Kali,
Here you go:
https://www.spandidos-publications.com/10.3892/or.2016.5110
https://www.sciencedirect.com/science/article/pii/S2152265016305687
In the second article, Dr. Cortes is the lead author. He is also my doctor who prescribed my 20 mg dasatinib (sprycel).
He is very experienced in P.E. issues and should be a great resource.
Regarding your doctors comment:
"He hasn’t been favorable of 20 due to fear I would develop resistance."
Your doctor is misinformed. Dosing levels and CML resistance are not related. Resistance is a viral/bacterial condition due to an external pathogen/ Cancer is a "self" genetic condition. Mutations leading to CML drug resistance are not caused by too low a drug dose. Drug dosing in CML needs to be customized to the individual. More is not better and less may actually be more effective not less. It makes sense when one realizes that TKI's can often "suppress" our immune system overall (i.e low counts). Getting the dose correct enables both our immune system and the drug to attack CML. This is why we can re-start our TKI's following cessation and in all cases reported regain response.
In the case of P.E. - you have an even better chance of having a terrific response on low dose since your immune system is already quite sensitized.
Lower dose is better if lower dose works. Increasing dose once response is already achieved can lead to a poorer outcome (especially increased side effects). As you are already PCRU - going back on 50 mg dasatnib once your P.E. resolves makes no sense.
You are in a good place to try cessation and test if your body can keep you in remission. Each month you get drug free is a month without toxicity. All TKI's are toxic.